Active	Status	Sponsor type	Region	Phase	Filter
7 Active 5 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Viltepso (viltolarsen) / Nippon Shinyaku, National Center of Neurology and Psychiatry
NCT04687020: Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)	Active, not recruiting	4	9	Canada, US	Viltolarsen	NS Pharma, Inc.	Duchenne Muscular Dystrophy	09/32	10/32
NCT04060199 / 2019-002076-13: Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)	Completed	3	77	Europe, Canada, US, RoW	Viltolarsen, NS-065/NCNP-01, Placebo	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	10/23	10/23
NCT04768062 / 2021-000122-10: Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)	Active, not recruiting	3	74	Europe, Canada, Japan, RoW	Viltolarsen, NS-065/NCNP-01	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	10/25	11/25
Galactic53, NCT04956289 / 2020-003653-30: Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD	Completed	2	20	Europe, US, RoW	Viltolarsen, NS-065/NCNP-01	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	06/23	07/23
brogidirsen (NS-089/NCNP-02) / Nippon Shinyaku, National Center of Neurology and Psychiatry
NCT05996003: NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)	Recruiting	2	20	US	NS-089/NCNP-02, Brogidirsen	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	09/26	09/26
NCT05135663: Extension Study of NS-089/NCNP-02 in DMD	Active, not recruiting	2	6	Japan	NS-089/NCNP-02	Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy (DMD)	01/26	07/26
OCH-NCNP1 / Eisai
NCT04211740: Phase II Clinical Trial of OCH-NCNP1	Completed	2	30	Japan	OCH-NCNP1, Placebo	National Center of Neurology and Psychiatry, Japan	Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive	05/23	05/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Viltepso (viltolarsen) / Nippon Shinyaku, National Center of Neurology and Psychiatry
NCT04687020: Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)	Active, not recruiting	4	9	Canada, US	Viltolarsen	NS Pharma, Inc.	Duchenne Muscular Dystrophy	09/32	10/32
NCT04060199 / 2019-002076-13: Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)	Completed	3	77	Europe, Canada, US, RoW	Viltolarsen, NS-065/NCNP-01, Placebo	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	10/23	10/23
NCT04768062 / 2021-000122-10: Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)	Active, not recruiting	3	74	Europe, Canada, Japan, RoW	Viltolarsen, NS-065/NCNP-01	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	10/25	11/25
Galactic53, NCT04956289 / 2020-003653-30: Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD	Completed	2	20	Europe, US, RoW	Viltolarsen, NS-065/NCNP-01	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	06/23	07/23
brogidirsen (NS-089/NCNP-02) / Nippon Shinyaku, National Center of Neurology and Psychiatry
NCT05996003: NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)	Recruiting	2	20	US	NS-089/NCNP-02, Brogidirsen	NS Pharma, Inc., Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy	09/26	09/26
NCT05135663: Extension Study of NS-089/NCNP-02 in DMD	Active, not recruiting	2	6	Japan	NS-089/NCNP-02	Nippon Shinyaku Co., Ltd.	Duchenne Muscular Dystrophy (DMD)	01/26	07/26
OCH-NCNP1 / Eisai
NCT04211740: Phase II Clinical Trial of OCH-NCNP1	Completed	2	30	Japan	OCH-NCNP1, Placebo	National Center of Neurology and Psychiatry, Japan	Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive	05/23	05/23